Neoleukin Therapeutics, Inc. (NASDAQ:NLTX – Get Free Report) traded down 9.1% on Tuesday . The stock traded as low as $22.03 and last traded at $22.34. 517,592 shares traded hands during trading, an increase of 933% from the average session volume of 50,104 shares. The stock had previously closed at $24.57.
Neoleukin Therapeutics Trading Down 1.4 %
The stock has a market capitalization of $206.94 million, a PE ratio of -7.08 and a beta of 1.11. The stock has a 50 day moving average price of $42.41 and a 200-day moving average price of $39.16.
Neoleukin Therapeutics Company Profile
Neoleukin Therapeutics, Inc, a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma.
Featured Articles
- Five stocks we like better than Neoleukin Therapeutics
- Using the MarketBeat Dividend Tax Calculator
- NVIDIA’s Blackwell Chips Set for Arizona Manufacturing by TSMC?
- Stock Analyst Ratings and Canadian Analyst Ratings
- Okta: Bullish Signals Suggest a Market Reversal Is Underway
- 5 Top Rated Dividend Stocks to Consider
- BlackRock Makes Waves With $12B Private Credit Acquisition
Receive News & Ratings for Neoleukin Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neoleukin Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
